This column was originally published on RealMoney on March 15 at 12:00 p.m. EST. It's being republished as a bonus for TheStreet.com readers.Sometimes it's so easy to get caught up in the daily ebb and flow of the market that we lose perspective. When volatility is on the rise, there is a real danger of zooming in on an increasingly short time frame and losing sight of the prevailing trend.
Please note that due to factors including low market capitalization and/or insufficient public float, we consider Novavax to be a small-cap stock. You should be aware that such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices. P.S. from TheStreet.com Editor-in-Chief, Dave Morrow:
It's always been my opinion that it pays to have more -- not fewer -- expert market views and analyses when you're making investing or trading decisions. That's why I recommend you take advantage of our free trial offer to TheStreet.com's RealMoney premium Web site, where you'll get in-depth commentary and money-making strategies from over 50 Wall Street pros, including Jim Cramer. Take my advice -- try it now.